Email not displaying correctly? View it in your browser.
Forefront
   Volume 4, Issue 1, March 2015
Follow us:   Facebook icon Twitter icon Youtube icon  
 
 
Robert B. Diasio, M.D Director's message: Mayo Clinic and multiple myeloma

Researchers continue strong history of advancing myeloma treatment.

 

  Features
Research

New criteria for diagnosing multiple myeloma
Validated biomarkers allow diagnosis before organ damage occurs.




Research

New 3-drug treatment for relapsed multiple myeloma
Drug combo provides unprecedented benefits, including longer remission.




Research

New data show atypical hyperplasia increases breast cancer risk
Findings may spur recommendations for screening MRI, medications.



Research

Nivolumab shows promise for Hodgkin's lymphoma
Early study suggests drug may fight cancer by optimizing immune function.




Research

Genotyping errors plague testing for tamoxifen therapy
Patients, clinicians need more data to assess the value of CYP2D6 testing.




Research

Quality of life may predict survival in aggressive lymphoma
Poor physical, emotional and social well-being may significantly reduce overall survival.


Research

Meet the investigator: Evette S. Radisky, Ph.D.
Dr. Radisky researches proteases in tumor progression and metastasis.



Important Links


Comments Comments?
We're interested in your feedback about this email.
Print Edition Want the Print Edition?
A print edition of Forefront is published annually. To request a free subscription, send your name and mailing address to forefrontmagazine@mayo.edu.
Mayo Clinic
Cancer Center


13400 E. Shea Blvd.
Scottsdale, AZ 85259

4500 San Pablo Road
Jacksonville, FL 32224

200 First Street SW
Rochester, MN 55905


 

Newsletter Archive | Contact Mayo Clinic Cancer Center

© 2015 Mayo Foundation for Medical Education and Research,
200 First Street SW, Rochester, MN 55905.
All rights reserved.
Terms of Use